Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver

Carcinogenesis

Volumn 25, Issue 6, 2004, Pages 941-949

  Arora, Annu ^a   Seth, Kavita ^a   Shukla, Yogeshwer ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYL SULFIDE; ANTINEOPLASTIC AGENT; BLEOMYCIN; DOXORUBICIN; GLYCOPROTEIN P; METHOTREXATE; ORGANOSULFUR DERIVATIVE; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ALLYL COMPOUND; SULFIDE;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG STRUCTURE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIVER CELL; MALE; MODULATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TISSUE SECTION; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; LIVER; PHYSIOLOGY;

ALLYL COMPOUNDS; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; K562 CELLS; LIVER; MALE; MICE; P-GLYCOPROTEINS; SULFIDES;

EID: 3042814442     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh060     Document Type: Article

References (45)

1. Gottesman,M.M. and Pastan,I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427.
2. Malayeri,R., Filipits,M., Suchomel,R.W., Zochbauer,S., Lechner,K. and Pirker,R. (1996) Multidrug resistance in leukemias and its reversal. Leuk. Lymph., 23, 451-458.
3. Ross,D.D., Wooten,P.J., Sridhara,R., Ordonez,J.V., Lee,E.J. and Schiffer,C.A. (1993) Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukaemia. Blood, 82, 1288-1299.
4. Fan,D., Beltran,P.J. and O'Brian,C.A. (1994) In Kellen,J.A. (ed.), Reversal of Multidrug Resistance in Cancer. CRC Press, Boca Raton, FL, pp. 93-125.
5. Ambudkar,A.S.V., Dey,S., Hrycyna,C.A., Ramachandra,M., Pastan,I. and Gottesman,M.M. (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39, 361-398.
6. Sugawara,I. (1990) Expression and functions of P-glycoprotein (MDR-1 gene product) in normal and malignant tissues. Acta Pathol. Jpn, 40, 545-553.
7. Sikic,B.I., Fisher,G.A., Lum,B.L., Halsey,J., Beketic-Oreskovic,L. and Chen,G. (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol., 40, 13-19.
8. Watanabe,T., Tsuge,H., Oh-Hara,T., Saito,M. and Tsuruo,T. (1995) Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in-vitro and in-vivo. Acta Oncol., 34, 235-241.
9. Mechetner,E.B. and Roninson,I.B. (1992) Efficient inhibition of P-glycoprotein mediated multidrug resistance with a monoclonal antibody. Proc. Natl Acad. Sci. USA, 89, 5824-5828.
10. Thierry,A.R., Rahman,A. and Dritschilo,A. (1993) Overcoming multidrug resistance in human tumour cells using free and liposomaly encapsulated antisense oligodeoxy-nucleotides. Biochem. Biophys. Res. Commun., 190, 952-960.
11. Ford,J.M. and Hait,W.N. (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199.
12. Pirker,R., Zochbauer,S., Kupper,H., Lassmann,A., Gsur,A., Frass,M., Krajnik,G., Knobl,P. and Lechner,A. (1995) Dexvirapamil as resistance modifier in acute myeloid leukaemia. J. Cancer Res. Clin. Oncol., 121 (suppl. 3), R21-R24.
13. Slate,L.D., Bruno,A.N., Casey,M.S., Zutshi,N., Garvin,J.L., Wu,H. and Pfister,R.J. (1995) RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance. Anticancer Res., 15, 811-814.
14. Pinto,J.J. and Rivlin,R.S. (2001) Antiproliferative effects of allium derivatives from garlic. J. Nutr., 131, 1058s-1060s.
15. Le Bon,A.M., Roy,C., Dupont,C. and Suschetet,M. (1997) In vivo antigenotoxic effects of dietary allyl sulfides in the rat. Cancer Lett., 114, 131-14.
16. Agarwal,K.C. (1996) Therapeutic actions of garlic constituents. Med. Res. Rev., 16, 111-124.
17. Fukushima,S., Takada,N., Hori,T. and Wanibuchi,H. (1997) Cancer prevention by organosulfur compounds from garlic and onion. J. Cell. Biochem., 27 (suppl.), 100-105.
18. Yang,C.S., Chhabra,S.K., Hong,J.Y. and Smith,T.J. (2001) Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J. Nutr., 131, 10415-10455.
19. Riggs,D.R., DeHaven,J.I. and Lamm,D.L. (1997) Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer, 79, 1987-1994.
20. Hong,Y.S., Ham,Y.A., Choi,J.H. and Kim,J. (2000) Effects of allyl sulfur compounds and garlic extract on the expression of Bcl-2, Bax and p-53 in non-small cell lung cancer cell lines. Exp. Mol. Med., 32, 127-134.
21. Wargovich,M.J., Imada,O. and Stephens,L.C. (1992) Initiation and post initiation chemopreventive effects of diallyl sulfide in esophageal carcinogenesis. Cancer Lett., 64, 39-42.
22. Singh,A. and Shukla,Y. (1998) Antitumour activity of diallyl sulfide on polycyclic aromatic hydrocarbon induced mouse skin carcinogenesis. Cancer Lett., 131, 209-214.
23. Singh,A. and Shukla,Y. (1998) Antitumour activity of diallyl sulfide in two stage mouse skin model of carcinogenesis. Biomed. Environ. Sci., 11, 258-263.
24. Shukla,Y., Arora,A. and Singh,A. (2002) Antitumourigenic potential of diallyl sulfide in Ehrlich ascites tumour bearing mice. Biomed. Environ. Sci., 15, 41-47.
25. Arora,A. and Shukla,Y. (2003) Induction of apoptosis by diallyl sulfide in DMBA-induced mouse skin tumors. Nutr. Cancer, 44, 89-93.
26. 1 and N-nitrosodiethylamine induced liver preneoplastic foci in rats fed naturally occurring allyl sulfides. Nutr. Cancer, 25, 61-70.
27. Lozzio,C.B. and Lozzio,R.B. (1975) Human chronic myelogenous leukaemia cell line with positive Philadelphia chromosome. Blood, 45, 321-324.
28. Mosmann,T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods, 65, 55-63.
29. Towbin,H., Staehelin,T. and Gordon,J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl Acad. Sci. USA, 76, 4350-4354.
30. Lowry,O.H., Rosenbrough,N.K., Farr,A.L. and Randall,R.J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
31. Laemmli,U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-682.
32. Gottesman,M.M. (1993) How cancer cells evade chemotherapy. Cancer Res., 53, 747-754.
33. Pastan,I. and Gottesman,M.M. (1993) Multiple drug resistance in human cancers. N. Engl. J. Med., 316, 385-427.
34. Roninson,I.B. (1992) The role of MDR-1 (P-glycoprotein) gene in multidrug resistance in-vitro and in-vivo. Biochem. Pharmacol., 43, 95-102.
35. Tsuruo,T., Oh-Hara,T. and Saito,H. (1986) Characteristics of vincristine resistance in vincristine resistant human myelogenous leukaemia K562. Anticancer Res., 6, 637-641.
36. Tan,B., Piwnica-Worms,D. and Ratner,L. (2000) Multidrug resistance transporters and modulation. Curr. Opin. Oncol., 12, 450-458.
37. Robert,J. (1997) Multidrug resistance reversal agents. Drugs Future, 22, 149-158.
38. Arora,A. and Shukla,Y. (2003) Modulation of P-glycoprotein mediated multidrug resistance by indole-3-carbinol. Cancer Lett., 189, 167-173
39. Christensen,J.C. and LeBlanc,G. (1996) Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res., 56, 574-581
40. Zhu,A., Wang,X. and Guo,Z. (2001) Study of tea polyphenols as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent). Nucl. Med. Biol., 28, 735-748.
41. Sadzuka,Y., Sugiyama,T. and Sonobe,T. (2000) Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol. Lett., 114, 155-162.
42. Ishikawa,M., Fujita,R., Takayanagi,Y. and Sasaki,K. (2000) Reversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizole. Biol. Pharm. Bull., 23, 112-115.
43. Zamora,J.M., Pearce,H.L. and Beck,W.T. (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemia cells. Mol. Pharmacol., 33, 454-462.
44. Brady,J.F., Ishizaki,H., Fukuto,J.M., Lin,M.C., Fadel,A., Gapac,J.M. and Yang,C.S. (1991) Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem. Res. Toxicol., 4, 642-647.
45. Jin,L. and Baillie,T.A. (1997) Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem. Res. Toxicol., 10, 318-327.